Oxygen Biotherapeutics, Inc. Expands Board of Directors

DURHAM, N.C., Oct. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc.
(OTC Bulletin Board: OXBO) today announced the expansion of the company's
board of directors with the addition of two new members. Appointed to the
company's board were Rene A. Eckert and The Honorable William A. Chatfield.
With their addition, the company board now has eight members.

Bill Chatfield most recently served as the Director of the U. S. Selective
Service System from November of 2004 to May of this year, having been
nominated by President George W. Bush and confirmed by the U.S. Senate. He was
directly responsible to the President for the management of the Selective
Service System. His background includes more than 30 years of experience
working with the executive and legislative branches of the Federal government.

Rene Eckert was Chairman, CEO & Partner at Boehme Filatex Inc. of Reidsville,
NC from 1981 to 2007. He started the specialty chemical company with two
partners in 1981. They formed the company into a leading North American
textile chemical corporation with subsidiaries in Canada and Mexico. In 2007
the corporation was sold to an international dyestuff company (Dystar).

"I'm very pleased that these two gentlemen have agreed to join our board,"
said Chris Stern, company chairman and CEO. "Rene Eckert has the business
acumen and experience in product R & D, production scale up, and product
manufacturing to help us bring Oxycyte(TM)-based products to the market. What
Bill Chatfield brings to the table is the kind of Federal government
experience and contacts, including the Department of Defense, that can be very
helpful as we grow our Defense Medicine(TM) business plan. Our board and
company will be stronger with their involvement."

About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative
pharmaceuticals and medical devices in the field of oxygen therapeutics and
Defense Medicine(TM). The company has developed a perfluorocarbon (PFC)
therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and
has out-licensed an implantable glucose sensor. These products are based upon
core technologies that include biomedical applications for PFCs as well as
medical and industrial applications for biosensors. Each of the product
candidates is designed with advantages over currently marketed products in
major markets including traumatic brain injury, sickle cell crisis, trauma,
wound care, decompression sickness, acute respiratory distress syndrome,
stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and
cosmetic applications which are being marketed under the Dermacyte name. More
information is available at www.oxybiomed.com.

SOURCE Oxygen Biotherapeutics, Inc.

Abe Wischnia, Abe Wischnia & Associates, +1-619-795-2345